Back to Authors

Zimmerman, Sarah K.

Mayo Clinic

Czech Academy of Sciences, Institute of Microbiology

Citations 1

Tuberculosis and Trimethoprim-Sulfamethoxazole
Forgacs, Pierre, Wengenack, Nancy L. , Hall, Leslie, Zimmerman, Sarah K., Silverman, Mark L., Roberts, Glenn D.

Antimicrobial Agents and Chemotherapy | June 30, 2009 | Volume: 53 | Issue: 11 | Pages: 4789-4793

10.1128/aac.01658-08 Get It

ABSTRACTThe sulfonamides were the first drugs with antituberculous effects. Their use was abandoned and basically forgotten with the advent of streptomycin and isoniazid combination treatment. There is a widespread belief, apparently based on testing a single isolate on questionable media, thatMycobacterium tuberculosisis resistant to trimethoprim-sulfamethoxazole (TMP-SMX). We saw a complex immunocompromised patient with tuberculosis who was initially treated with TMP-SMX without antituberculous drugs and defervesced on this treatment. An isolate ofM. tuberculosisfrom this patient was found to be sensitive to TMP-SMX. We examined how frequentlyM. tuberculosisis sensitive to TMP-SMX. Isolates were tested for susceptibility to TMP-SMX on supplemented Middlebrook 7H10 plates. We found that 43 of 44 (98%) isolates ofM. tuberculosiswere susceptible to the combination of ≤1 μg/ml of TMP and 19 μg/ml of SMX (≤1/19 μg/ml). Thus, the vast majority of ourM. tuberculosisisolates were susceptible to TMP-SMX at an MIC similar to that forMycobacterium kansasii,Mycobacterium marinum, and sensitive rapidly growing mycobacteria, organisms successfully treated with TMP-SMX as part of the treatment regimen. It is possible that TMP-SMX may be useful in treating patients with multiple-drug-resistant and extended drug-resistant tuberculosis. We feel that a clinical trial looking at the effectiveness of TMP-SMX as an antituberculous drug is worthwhile.